Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/26/2026

1. INTU
2. DKS
3. NVDA
4. META
5. ZM

6. SPY
7. SMTC
8. NCNO
9. BOX
10. CRM

Get Alerts PTLA Hot Sheet

Price: $18.03 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March:

Cowen and Company’s 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston.
Oppenheimer’s 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 10:55 a.m. Eastern Time in New York.

Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.

About Portola Pharmaceuticals, Inc.Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.

Investor Contact: Cara MillerPortola Pharmaceuticals[email protected]

Media Contact:Laurie MasonsonW2O Group[email protected]